| Title: | Exploring a genetic basis for the metabolic perturbations in ME/CFS using UK biobank |
| Journal: | iScience |
| Published: | 1 Jan 2026 |
| DOI: | https://doi.org/10.1016/j.isci.2025.114316 |
Publication 16807
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a clinically heterogeneous disease lacking approved therapies. To assess genetic susceptibility toward a specific metabolic phenotype, we performed a genome-wide association study on plasma biomarker levels (mGWAS) in patients with ME/CFS (n = 875) and healthy controls (HCs) (n = 36,033). We identified 112 significant SNP-biomarker associations in ME/CFS, compared with 4,114 in HCs. Two SNPs specific to ME/CFS, mapping to HSD11B1 and SCGN, were associated with phospholipids in extra-large very low-density lipoproteins (VLDLs) and total fatty acids, respectively. Genetic effects of VLDL associations were among the least correlated between ME/CFS and HCs. Heterogeneity tests found differential effects for several lipid traits at ADAP1, NR1H3, and CD40, which are involved in immune regulation. ME/CFS mGWAS statistics were decomposed to uncover shared genetic-metabolic patterns, where enrichment analysis highlighted pathways in lipid metabolism, neurotransmitter transport, and inflammation. These findings provide a genetic and molecular rationale for patient heterogeneity and suggest a polygenic predisposition in which many small-effect variants may jointly perturb metabolic mechanisms.</p>
7 Authors
- Katherine Huang
- Muhammad Muneeb
- Natalie Thomas
- Elena K. Schneider-Futschik
- Paul R. Gooley
- David B. Ascher
- Christopher W. Armstrong
1 Application
| Application ID | Title |
|---|---|
| 79568 | Precision medicine for ME/CFS using omics data and machine learning |
Enabling scientific discoveries that improve human health